产品说明书
AS1842856
 |
同义名 : | FOXO1 Inhibitor |
| CAS号 : | 836620-48-5 | |
| 货号 : | A169136 | |
| 分子式 : | C18H22FN3O3 | |
| 纯度 : | 99%+ | |
| 分子量 : | 347.384 | |
| MDL号 : | MFCD30718173 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,Room temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 4 mg/mL(11.51 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | The forkhead box protein O1 (Foxo1) is a transcription factor that plays a critical role in hepatic gluconeogenesis. AS-1842856 is a Foxo1 inhibitor with an IC50 value of 0.03μM. In HepG2 cells transiently transfected with vectors carrying human Foxo1, AS-1842856 inhibited Foxo1 activity in a dose-dependent manner. AS-1842856 at a concentration of 0.1μM decreased Foxo1-mediated transactivation by 70%. Treatment of Fao cells with AS-1842856 for 18 hours inhibited the mRNA expression of G6Pase and PEPCK with IC50 values of 0.13μM and 0.037μM, respectively. Treatment of Fao cells with AS-1842856 (0.1 – 10μM) alone or in combination with insulin (0.1 – 10nM) did not affect the phosphorylation state of Akt, ERK, or S6K. In ICR mice, oral administration of AS-1842856 (100mg/kg) at three time points (8AM, 6PM, and 8AM on the second day) during 26-h fasting significantly reduced the mRNA expression of G6Pase and PEPCK in the liver, but did not alter the plasma glucose level.[3] | ||
| 作用机制 | AS-1842856 inhibits Foxo1-mediated transactivation by directly binding to Foxo1.[3] | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.88mL 0.58mL 0.29mL |
14.39mL 2.88mL 1.44mL |
28.79mL 5.76mL 2.88mL |
| 参考文献 |
|---|